- Home
- General Medicine
- Brolucizumab in nAMD: Efficacy, Durability, and Safety Insights from HAWK and HARRIER Trials

3w3 min read
Medical Article
Introduction: Age-related macular degeneration (AMD), especially the neovascular (wet) form, remains a leading cause of irreversible vision loss worldwide (1). The advent of anti-VEGF therapies, such as ranibizumab, aflibercept, and bevacizumab, revolutionized disease management, significantly improving visual outcomes (1). However, these treatment

Brolucizumab in nAMD: Efficacy, Durability, and Safety Insights from HAWK and HARRIER Trials
2631 Reached
Similar Content

Woman presented with Fever of Unknown Origin
7717 Reached93 Comments19 Likes

How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes

Male with Jaw Pain and Abdominal Bloating
790 Reached24 Comments26 Likes

Case of Adolescent with Severe Macrocytic Anaemia
52484 Reached503 Comments51 Likes

Suicide Attempt of Female with Paracetamol, INH And Ibuprofen Poisoning
490 Reached14 Comments15 Likes